$AEON News

AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

AEON: Initiating Coverage – Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar

Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

AEON Biopharma Designates Paul Lee As Chief Regulatory Office

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®

AEON Biopharma Announces Final, Expanded Primary Structure Results And Preliminary Disulfide Bond Characterization Data Providing Complementary Evidence Supporting Molecular Similarity Of ABP-450 To BOTOX

HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Q2 EPS $(0.02) Beats $(0.12) Estimate

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

AEON Biopharma Regains NYSE American Compliance

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

AEON Biopharma Presents New Analytical And Functional Data Supporting Biosimilarity Of ABP-450 To BOTOX At 68th Annual Scientific Meeting Of AHS

Why You Might Be Interested In Aeon Co. (M) Bhd. (KLSE:AEON) For Its Upcoming Dividend

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Q1 EPS $(0.29) Misses $(0.13) Estimate